{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T09:08:48Z","timestamp":1790500128647,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T00:00:00Z","timestamp":1532908800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.01774","type":"journal-article","created":{"date-parts":[[2018,7,30]],"date-time":"2018-07-30T08:36:36Z","timestamp":1532939796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":139,"title":["Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Han","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chushu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Yuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"536","DOI":"10.3389\/fphar.2018.00536","article-title":"Regulation of PD-L1: emerging routes for targeting tumor immune evasion","volume":"9","author":"Wang","year":"2018","journal-title":"Front Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/PPO.0000000000000060","article-title":"PD-1 as an immune modulatory receptor","volume":"20","author":"Yao","year":"2014","journal-title":"Cancer J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5209","DOI":"10.1158\/0008-5472.CAN-12-1187","article-title":"PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines","volume":"72","author":"Peng","year":"2012","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu Rev Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0061-3","article-title":"IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1","author":"Dill","year":"2018","journal-title":"Mod Pathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2326-6066.CIR-17-0122","article-title":"Tumor PDCD1LG2 (PD-L2) expression and the lymphocytic reaction to colorectal cancer","volume":"5","author":"Masugi","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/1751-2980.12538","article-title":"Rise of PD-L1 expression during metastasis of colorectal cancer: implications for immunotherapy","volume":"18","author":"Wang","year":"2017","journal-title":"J Dig Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1327494","DOI":"10.1080\/2162402X.2017.1327494","article-title":"PD-L2 expression in colorectal cancer: independent prognostic effect and targetability by deglycosylation","volume":"6","author":"Wang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nature06489","article-title":"Identification of cells initiating human melanomas","volume":"451","author":"Schatton","year":"2008","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/0008-5472.CAN-09-1592","article-title":"Modulation of T-cell activation by malignant melanoma initiating cells","volume":"70","author":"Schatton","year":"2010","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6159214","DOI":"10.1155\/2018\/6159214","article-title":"Predicting and understanding cancer response to treatment","volume":"2018","author":"Callari","year":"2018","journal-title":"Dis Markers"},{"key":"B17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1172\/JCI32453","article-title":"Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis","volume":"118","author":"Popivanova","year":"2008","journal-title":"J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","article-title":"Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth","volume":"162","author":"Kleffel","year":"2015","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e1408747","DOI":"10.1080\/2162402X.2017.1408747","article-title":"Blockade of tumor-expressed PD-1 promotes lung cancer growth","volume":"7","author":"Du","year":"2018","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1002\/hep.29360","article-title":"Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1","volume":"66","author":"Li","year":"2017","journal-title":"Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev.immunol.24.021605.090535","article-title":"A molecular perspective of CTLA-4 function","volume":"24","author":"Teft","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/jdv.14633","article-title":"Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab","volume":"32","author":"Mohr","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","article-title":"Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies","volume":"27","author":"Philips","year":"2015","journal-title":"Int Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"B32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.3564","article-title":"Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas","volume":"48","author":"Campbell","year":"2016","journal-title":"Nat Genet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nmeth.1607","article-title":"A roadmap to generate renewable protein binders to the human proteome","volume":"8","author":"Colwill","year":"2011","journal-title":"Nat Methods"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01774\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T12:59:45Z","timestamp":1571662785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.01774\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,30]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2018.01774"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.01774","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,30]]},"article-number":"1774"}}